EOM Pharmaceuticals Holdings, Inc. IMUC
Set alert
At close · Oct 30
- YTD
- +2.82%
- 1 year
- -59.44%
- Open
- 0.0726
- Prev close
- 0.075
- Mkt cap
- 9.23M
- Vol
- 180
- Avg vol
- 1.92K
- EPS
- 1.03
- P/E
- 0.07
- Div yield
- 0.00%
More statistics
- Low
- 0.0726
- High
- 0.0726
- Forward P/E
- -0.05
- Beta
- 2.71
- Short ratio
- 8.46
- Inst. own
- 4.30%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 30, 2019
- 50-d avg
- 0.108512
- 200-d avg
- 0.212253
- 1y target
- 5.00
News
7 months ago defenseworld.net
EOM Pharmaceutical (OTCMKTS:IMUC) & Siga Technologies (NASDAQ:SIGA) Financial Survey
Siga Technologies (NASDAQ: SIGA - Get Free Report) and EOM Pharmaceutical (OTCMKTS:IMUC - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the…
10 months ago defenseworld.net
EOM Pharmaceutical (OTCMKTS:IMUC) Trading 139% Higher – Still a Buy?
Shares of EOM Pharmaceutical Holdings, Inc. (OTCMKTS:IMUC - Get Free Report) rose 139% during trading on Monday. The company traded as high as $0.2180 and last traded at $0.2180. Approximately 12,218…
2 years ago prnewswire.com
EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613
MONTVALE, N.J. , Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug candidate EOM613.
3 years ago prnewswire.com
EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil
Results indicate that EOM613 treatment mitigates cytokine release in patients with COVID-19 pulmonary vascular inflammation MONTVALE, N.J. , Sept. 6, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings,…
5 years ago prnewswire.com
ImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market
LOS ANGELES, June 28, 2021 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that the Company has taken steps to comply with amended Rule 15c2-11 under…